Therapy
Health
Pharmaceutical
Sarepta Therapeutics
$118.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$118.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.59 (2.19%) Today
-$2.34 (-1.94%) After Hours
Why Robinhood?
You can buy or sell SRPT and other stocks, options, ETFs, and crypto commission-free!
About
Sarepta Therapeutics, Inc. Common Stock (DE), also called Sarepta Therapeutics, is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. Read More The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Employees
499
Headquarters
Cambridge, Massachusetts
Founded
1980
Market Cap
8.96B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.26M
High Today
$121.22
Low Today
$118.23
Open Price
$119.31
Volume
238.30K
52 Week High
$176.50
52 Week Low
$90.00
Collections
Therapy
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Technology
US
North America
News
Yahoo Finance48m
Market Weekly Review: Lower Prices Create Buying Opportunities
Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011. After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your Advantage Investors tend to shy away from volatility, which is a word that generally is only mentioned when prices are...
Seeking AlphaMay 23
Independent research group finds scant evidence of efficacy for Sarepta's exon-skipping DMD meds
A report prepared for the New England Comparative Effectiveness Public Advisory Council (CEPAC) by the Institute for Clinical and Economic Review (ICER), an independent non-profit research organization that evaluates medical evidence, did not find much evidence supporting the efficacy of Sarepta Therapeutics' (NASDAQ:SRPT) Exondys 51 (eteplirsen), golodirsen or PTC Therapeutics' (NASDAQ:PTCT) Emflaza (deflazacort) in the clinical studies conducted to date.
Price Paid on Robinhood
18% Higher
Right Now
52 Week Low
$90.00
Average Price Paid
$100.66
52 Week High
$176.50
Earnings
-$1.68
-$1.19
-$0.69
-$0.20
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours